Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome
JAMA Neurol 75:353-359, Martinez-Ramirez, D.,et al, 2018
A Trial of Scheduled Deep Brain Stimulation for Tourette Syndrome
JAMA Neurol 70:85-94, Okun, M.,et al, 2013
Deep Brain Stimulation for Tourette Syndrome
Neurol 73:e87-e90, Black,K., 2009
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Randomized, Controlled Trial of Cannabis-Based Medicine in Central Pain in Multiple Sclerosis
Neurol 65:812-819,788, Rog,D.J.,et al, 2005
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Use of GPT-4 to Diagnose Complex Clinical Cases
NEJM AI doi:10.1056/AIp2300031, Eriksen,A.V.,et al, 2023
Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation of Chronic Back and Leg Pain
JAMA Neurol 79:251-260, Mekhail, N.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Differential Diagnosis Checklists Reduce Diagnostic Error Differentially: A Randomised Experiment
Med Educ 55:1172-1182, Kammer, J.E.,et al, 2021
The Durability of Minimally Invasive Lumbar Decompression Procedure in Patients with Symptomatic Lumbar Spinal Stenosis:Long-term Follow-up
Pain Practice 21:826-835, Mekhail,N.,et al, 2021
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy
NEJM 378:625-635, Mercuri, E.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Palliative CT-Guided Cordotomy for Medically Intractable Pain in Patients with Cancer
AJNR 38:387-390, Shepherd, T.M.,et al, 2017
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Surgery for Drug-Resistant Epilepsy in Children
NEJM 377:1639-1647, Dwivedi, R.,et al, 2017
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
NEJM 377:1713-1722,1786, Mendell, J.R.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Effects of Aspiring on Risk and Severity of Early Recurrent Stroke After Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials
Lancet: 388:365-375, 312, Rothwell, P.M.,et al, 2016
Diagnostic Yield and Safety of Brain Biopsy for Suspected Primary Central Nervous System Angiitis
Stroke 47:2127-2129, Torres, J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
The Effectiveness of Electronic Differential Diagnoses (DDX) Generators: A Systematic Review and Meta-Analysis
PLoS ONE 11:e0148991, Riches, N.,et al, 2016
Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy
JAMA 313:285-293, Jobst, B.C. & Cascino, G.D., 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015